Abstract Submission Period

Session Type and Category

Symposium

• Broad look at immunity, inflammation, and metabolism involving the digestive organ crosstalk

  Living organisms comprise organ systems, each with their own unique regulatory mechanisms that generate complex in vivo responses. All these systems include intricate regulatory mechanisms around the organs, such as those found between the liver, pancreas, biliary tract, and gastrointestinal tract and the brain and autonomic nervous system. These are also found between the heart, kidneys, and even among muscles and bone marrow. Recent advances have led to a detailed understanding of the basic physiological functions of these organ systems and organs within homeostatic or regulatory mechanisms. Consequently, interdisciplinary studies encompassing areas including metabolism, intestinal bacteria, immunology, tissue microenvironment, extracellular vesicles, imaging, and multi-omics have revealed interorgan communication networks that considerably facilitate drug discovery and development. In this session, our primary focus will be on organs within the digestive system while also addressing those involved in immunity, inflammation, metabolism, and the nervous system. We will provide an overview and further discuss the latest findings spanning various organs and interdisciplinary fields, without limiting ourselves to a specific organ or academic field.

• Recent Advances in Minimally Invasive Endoscopic Treatment for Gastrointestinal Tumors

  More than 20 years after the development of endoscopic submucosal dissection (ESD), endoscopic treatment is becoming more sophisticated as the development of devices and techniques. ESD of the duodenum, previously considered very high-risk, has been reported its improved outcomes, mainly by high-volume centers. Dissection in the proper muscular layer and even full thickness resection is now also being performed. There has also been significant progress in protection of wound by endoscopic suturing and covering material those enable challenging procedures described above. Furthermore, multidisciplinary treatment combining endoscopic therapy and chemoradiotherapy is being attempted. In this session, we would like to discuss about the cutting edge of endoscopic treatment for gastrointestinal tumors.

• Systemic therapies for advanced hepatocellular carcinoma

  Combination immunotherapies, including atezolizumab + bevacizumab and durvalumab + tremelimumab, are currently employed as 1st line systemic treatments for advanced hepatocellular carcinoma. The treatment of advanced hepatocellular carcinoma is regarded as having reached a major turning point, because data from ongoing clinical trials will soon be published. Findings regarding the clinicopathological background of hepatocellular carcinoma, biomarkers, the cancer microenvironment, and other topics relevant to the selection and effectiveness of combination immunotherapy have been compiled. However, various issues remain unresolved, such as establishing effective treatment sequences after combination immunotherapy, identifying strategies for conversion treatment to cure hepatocellular carcinoma in responded cases, and elucidating the pathology of immune-related adverse events and their effective management. To address the above issues, the present symposium will feature presentations from a wide range of perspectives to contribute to future treatment and research on systemic therapy for advanced hepatocellular carcinoma and further discussions, including future prospects.

• Current Status and Future Prospects for Management of Acute and Chronic Pancreatitis

  Over the past 30 years, the treatment outcomes for both acute and chronic pancreatitis have improved significantly. The fatality rate for severe cases of acute pancreatitis has dropped from 30% to 6%, with notable improvements in early stage fatality rates. Moreover, the application of minimally invasive treatments for late-stage infectious complications has enhanced treatment outcomes. In the context of chronic pancreatitis, the concept of early chronic pancreatitis has been introduced, and the effectiveness and limitations of endoscopic treatment, and surgery have been clarified. On the other hand, several challenges remain for acute pancreatitis. Including the development and implementation of additional treatments during the early stages of disease onset, determination of the optimal timing for therapeutic interventions in infectious complications, and the appropriate application of each treatment modality. Challenges in chronic pancreatitis include establishing diagnostic methods for early chronic pancreatitis and developing treatments that focus on improving the overall physical state, including the prevention of carcinogenesis. Furthermore, the widespread adoption of established treatments remains a significant issue for both acute and chronic pancreatitis. In this symposium, we will discuss the current status and future prospects of pancreatitis managements limited to these issues.

Free Paper (Oral Session)

Category A

Category B

Category C

Category D

Submission Guidelines

Abstracts must be submitted online through the official online abstract submission system. Abstracts sent via e-mail will not be accepted.

This system has been confirmed to work with [Google Chrome], [Microsoft Edge], and [Safari]. Please do not use any other browser. *Safari can be used with ver.2.0.3 (417.9.2) or later versions. Versions less than the above cannot be used.

For security reasons, if you do not proceed to the next screen within 120 minutes, the session will time out.

• Language for abstract, presentation and presentation slides: English
• Number of words:
  The entire body of the abstract must not exceed 1,700 characters. Spaces are included in this number. If you register a diagram, it must be no more than 1,100 characters.
  Please do not include the title, authors' names and affiliations in the abstract field.
• Diagram
  You can only submit one diagram and in JPEG or GIF format. We do not allow greyscale images. Charts will be automatically resized to fit 3cm × 4cm. Please consider how you would like your graphs to appear.
• The number of co-authors is limited to 9 persons per abstract for Symposium (Main Session). And Free Paper (Oral Session) limited to 19 persons per abstract.

Conflict of Interest

In accordance with the Japanese Society of Gastroenterology Conflict of Interest Management Guidelines all speakers are required to disclose their conflicts of interest for three years prior to abstract submission.

If there is a conflict of interest, please register it through the system at the time of abstract submission.

Abstract Submission

After you complete the registration, an ID and password will be displayed on the screen.To prepare for the event that the email does not arrive, please be sure to save these details.

To change or update your registration information, please click below. (ID and password are required)

Notification of Abstract Acceptance

Notification of acceptance or rejection will be announced by email at the end of January 2025 to the email address you registered when submitting your abstract. The detailed information about presentation schedule, such as date and place, is going to be mentioned in the notification of acceptance.

For Inquiries about Abstract Submission

c/o Japan Convention Services, Inc.
E-mail: endai-111jsge[A]convention[D]co[D]jp( Please change [A] to @ and [D] to. )